ImmunoPrecise Antibodies Ltd. Files 6-K, Incorporates Exhibits
Ticker: HYFT · Form: 6-K · Filed: Sep 18, 2024 · CIK: 1715925
| Field | Detail |
|---|---|
| Company | Immunoprecise Antibodies LTD. (HYFT) |
| Form Type | 6-K |
| Filed Date | Sep 18, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, registration-statement
TL;DR
IPA files 6-K, incorporates exhibits into F-3s. Standard update.
AI Summary
ImmunoPrecise Antibodies Ltd. filed a Form 6-K on September 18, 2024, to report information for the month of September 2024. The filing incorporates by reference Exhibit 99.1 into its existing F-3 registration statements (File Nos. 333-273197 and 333-281312). The company is incorporated in A1 and its fiscal year ends on April 30.
Why It Matters
This filing updates the market on ImmunoPrecise Antibodies Ltd.'s regulatory submissions and incorporates previously filed information into ongoing registration statements, which can be relevant for future capital raising activities.
Risk Assessment
Risk Level: low — This filing is a routine report of foreign private issuer information and does not appear to contain significant new financial or operational developments.
Key Players & Entities
- ImmunoPrecise Antibodies Ltd. (company) — Filer of the 6-K report
- 333-273197 (dollar_amount) — File number for a registration statement on Form F-3
- 333-281312 (dollar_amount) — File number for a registration statement on Form F-3
FAQ
What is the purpose of this Form 6-K filing?
The purpose of this Form 6-K filing is to report information for the month of September 2024 by ImmunoPrecise Antibodies Ltd., a foreign private issuer.
Which registration statements are being updated by this filing?
Exhibit 99.1 of this Form 6-K is incorporated by reference into the Registrant's Registration Statements on Form F-3, specifically File Nos. 333-273197 and 333-281312.
What is the principal executive office address of ImmunoPrecise Antibodies Ltd.?
The principal executive office address is 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8.
Does ImmunoPrecise Antibodies Ltd. file annual reports under Form 20-F or Form 40-F?
ImmunoPrecise Antibodies Ltd. indicates it files annual reports under Form 20-F.
When is ImmunoPrecise Antibodies Ltd.'s fiscal year end?
ImmunoPrecise Antibodies Ltd.'s fiscal year ends on April 30.
Filing Stats: 174 words · 1 min read · ~1 pages · Grade level 11 · Accepted 2024-09-17 17:42:17
Filing Documents
- executive_comp_-_6-k.htm (6-K) — 29KB
- ipa-ex99_1.htm (EX-99.1) — 580KB
- img36100363_0.jpg (GRAPHIC) — 90KB
- 0000950170-24-107432.txt ( ) — 734KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. IMMUNOPRECISE ANTIBODIES LTD. Date: September 17, 2024 By: /s/ Kristin Taylor Name: Kristin Taylor Title: Chief Financial Officer EXHIBIT INDEX Exhibit Description 99.1